Open AccessFindings from the EMPEROR-Reduced study are a tool to improve care for patients with chronic heart failure with reduced ejection fraction.Resolution of the Regional Scientific Meeting of Experts of the Southern Federal District
Author(s) -
М. М. Батюшин,
Алла Анатольевна Вачугова,
С. Р. Гиляревский,
Irina Dzherieva,
Н. А. Закарьяева,
М. В. Зыков,
V. Ivanenko,
У. С. Исаева,
С. Г. Канорский,
М. А. Киселева,
И. М. Курбанова,
Ю. М. Лопатин,
С. В. Недогода,
Г. А. Санеева,
Е. С. Славицкая,
Е. Л. Хадарцева
Publication year - 2021
Publication title -
ûžno-rossijskij žurnal terapevtičeskoj praktiki
Language(s) - English
Resource type - Journals
ISSN - 2712-8156
DOI - 10.21886/2712-8156-2021-2-2-104-110
Subject(s) - emperor , ejection fraction , heart failure , medicine , empagliflozin , chronic renal failure , cardiology , intensive care medicine , history , ancient history , endocrinology , diabetes mellitus , type 2 diabetes mellitus
At online scientific expert meeting of the South region held on October 3, 2020, the results of the international multicenter study EMPEROR-Reduced were discussed. Number of proposals and recommendations were adopted for the further study of the cardiovascular and renal effects of empagliflozin, its use in clinical practice in patients with chronic heart failure.